A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure

Table 2

Mean IOP change from baseline in the modified intent-to-treat population (2-sample t-test).

Visit	Mean IOP change from baseline (SD), mmHg		Between-treatment difference^a (95% CI), mmHg	value
	TFC	DFC
Week 1	−10.18 (3.15)	−8.90 (3.04)	−1.28 (−2.19, −0.37)	0.006
n	91	89
Week 2	−10.44 (2.90)	−9.04 (2.91)	−1.40 (−2.24, −0.55)	0.001
n	93	94
Week 4	−10.14 (2.97)	−9.23 (2.27)	−0.92 (−1.68, −0.15)	0.019
n	93	94
Week 8	−9.84 (3.00)	−8.99 (2.83)	−0.85 (−1.69, −0.01)	0.047
n	93	94
Week 12^b	−10.03 (2.66)	−9.18 (2.57)	−0.85 (−1.60, −0.09)	0.028
n	93	94

CI: confidence interval; DFC: dual fixed-combination; IOP: intraocular pressure; SD: standard deviation; TFC: triple fixed-combination. ^aNegative values indicate greater IOP lowering with TFC than DFC. ^bPrimary efficacy variable.